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Summary
 
The Ly-6 superfamily of cell surface molecules includes CD59, a potent regulator of the com-
plement system that protects host cells from the cytolytic action of the membrane attack com-
plex (MAC). Although its mechanism of action is not well understood, CD59 is thought to
prevent assembly of the MAC by binding to the C8 and/or C9 proteins of the nascent com-
plex. Here a systematic, structure-based mutational approach has been used to determine the
region(s) of CD59 required for its protective activity. Analysis of 16 CD59 mutants with single,
highly nonconservative substitutions suggests that CD59 has a single active site that includes
Trp-40, Arg-53, and Glu-56 of the glycosylated, membrane-distal face of the disk-like extra-
cellular domain and, possibly, Asp-24 positioned at the edge of the domain. The putative active
site includes residues conserved across species, consistent with the lack of strict homologous re-
striction previously observed in studies of CD59 function. Competition and mutational analy-
ses of the epitopes of eight CD59-blocking and non-blocking monoclonal antibodies con-
firmed the location of the active site. Additional experiments showed that the expression and
function of CD59 are both glycosylation independent.
 
C
 
omplement is a tightly regulated system of proteins
that protects a host from infection by invading micro-
organisms. Complement-mediated immune responses cul-
minate in the assembly of the membrane attack complex
(MAC)
 
1
 
 at the membrane of the foreign organism, forming
a pore that leads to osmotic lysis. The cytolytic action of
complement is the basis of hyperacute rejection reactions
which result in the destruction of xeno- and allografts after
transplantation (1). Of the three major membrane-bound pro-
teins that protect host cells from lysis by complement, CD59
(also called membrane inhibitor of reactive lysis [MIRL],
protectin, HRF20, and H19), decay-accelerating factor,
and membrane cofactor protein, the most potent inhibitor
on human endothelial cells is CD59 (2). Deficiency of
CD59 is the primary cause of erythrocytic hemolysis ob-
served in patients with paroxysmal nocturnal hemoglobin-
uria (3, 4). The importance of CD59 is also underscored by
the tumor virus Herpesvirus saimiri, which encodes a pro-
tein homologous to CD59 apparently as a means of evad-
ing the immune system of its host (5, 6).
CD59 appears to function as an inhibitor of complement
by binding to C5b-8 or C5b-9 of the assembling MAC,
thereby preventing incorporation of the multiple copies of
C9 required for complete formation of the osmolytic pore
(7, 8). Despite sequence identities as low as 40%, the pri-
mate, rat, pig, and sheep homologues are able to function
across species barriers, albeit to varying degrees of effi-
ciency (9–11). CD59 may also participate in signal trans-
duction events leading to activation of T cells, thymocytes,
and neutrophils (12). Although binding between CD59
and CD2 has been implicated in this mechanism of activa-
tion (13, 14), other groups have been unable to detect a
specific interaction between these two proteins (15, 16).
CD59 is a widely distributed, glycosylphosphatidylinosi-
tol (GPI)-anchored cell surface protein of 
 
z
 
20 kD belong-
ing to the Ly-6 superfamily (Ly-6SF) of cell surface pro-
teins. Ly-6 molecules were first identified in the mouse
serologically and, as such, were among the first cell surface
molecules identified (reviewed in reference 17). Neverthe-
less, with the exceptions of CD59 and the urokinase plas-
minogen activator receptor (reviewed in reference 18), the
functions of Ly-6SF molecules are poorly understood. CD59
is the only Ly-6SF protein for which a three-dimensional
 
1
 
Abbreviations
 
 
 
used in this paper:
 
 CHO, Chinese hamster ovary; GPI, glyco-
sylphosphatidylinositol; Ly-6SF, Ly-6 superfamily; MAC, membrane at-
tack complex; MIRL, membrane inhibitor of reactive lysis; NHS, normal
human serum; NMR, nuclear magnetic resonance; RT, room tempera-
ture.
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structure has been determined. Nuclear magnetic reso-
nance (NMR) spectroscopic analyses of human CD59 re-
vealed a single disk-like extracellular domain, formed by
single two- and three-stranded 
 
b
 
-sheets and a short 
 
a
 
-helix,
that is attached to the GPI anchor by a seven residue stalk
(19, 20). The topology of the extracellular domain is simi-
lar to that of snake venom neurotoxins, consistent with the
idea that these two groups of molecules evolved from a
common precursor as first proposed on the basis of se-
quence comparisons (21). Unlike the mouse Ly-6 proteins,
however, CD59 is 
 
N
 
-glycosylated at N18 (22) and this site
is conserved in all known mammalian CD59 sequences ex-
cept rat CD59 in which the site is shifted by two residues
to N16 (23). The contribution of the 
 
N
 
-glycan to the
function of the protein is controversial, however, as its re-
moval or modification has been variously reported to re-
duce costimulation of proliferation (24), and to eliminate
(25), enhance (26), or have no effect on (27, 28) the pro-
tective activity of CD59.
To date, no active site of any Ly-6SF molecule has been
characterized. The available data are consistent with the
proposal that the alpha chain of C8 and the “b” domain of
C9 compete for a single binding site on CD59 (29, 30) but
the identity of this site is unknown. Ferriani et al. (31)
showed that a tryptic fragment of CD59, including disul-
fide bonded peptides consisting of residues 1–14, 15–30,
and 39–41, is able to bind to nascent C5b-8, whereas a
study of synthetic peptides by Nakano et al. (32) suggests
that the active site is contained within residues 27–38. Kief-
fer et al. (19) proposed that the non-glycosylated face of
CD59 represents a potential ligand binding site because it is
relatively hydrophobic and has a series of solvent-exposed
phenylalanine and tyrosine residues reminiscent of other
sites of protein–protein interaction (33). Consideration of
the tertiary structure of CD59, in the context of the ana-
lysis of the tryptic fragment by Ferriani et al. (31), led
Fletcher et al. (20) to favor residues 20-24 which form a
loop on the edge of the domain. Finally, guided by similar-
ities in the rat and human CD59 protein sequences, Rush-
mere et al. (23) also concluded that the active site could be
centred on loop residues 20-24 but drew attention to a
conserved hydrophobic pocket lying on the glycosylated
face of the extracellular domain between the 
 
a
 
-helix and
the central 
 
b
 
-sheet. In the present study, site-specific muta-
tions of human CD59 have been used to define the regions
of the protein required for its complement-inhibitory ac-
tivity and to examine the role of the glycosylation of the
molecule.
 
Materials and Methods
 
Genes and Antibodies.
 
Human CD59 cDNA was obtained
from Professor Herman Waldmann (Sir William Dunn School of
Pathology, Oxford, UK) and Dr. David L. Simmons (Institute of
Molecular Medicine, Oxford, UK). The YTH53.1 hybridoma
was also obtained from Professor Waldmann. The anti-CD59
monoclonal antibody BRIC 229 was purchased from IBGRL (Els-
tree, UK); antibody 2/24 was a gift from Dr. A. Fletcher (Austra-
lian Red Cross Society, Sydney, NSW, Australia); antibodies
MEM43 and MEM43/5 were gifts from Dr V. Horejsi (Czech
Academy of Sciences, Prague); antibody A35 was prepared in
house (B.P.M., unpublished); antibodies HC1 and HC2 were
gifts from Dr. S. Meri (University of Helsinki, Finland). The
polyclonal antisera specific for human CD59 and for Chinese
hamster ovary (CHO) cell membranes were prepared in house
using standard methods.
 
Mutagenesis and Expression of CD59.
 
A Bam H1 fragment
containing the translated region of a CD59 complementary DNA
(22) was subcloned into the expression vector pEF-BOS (34).
Site-specific mutations were introduced into the gene by in vitro
mutagenesis using a commercial kit (Muta-Gene Version 2; Bio-
rad) following the manufacturer’s directions. For all mutants, the
presence of the desired mutation and fidelity of the part of the
gene encoding the rest of the fully processed protein was con-
firmed by dideoxy sequencing.
 
Transfection and Expression.
 
CHO cells, in Optimem medium
(Life Technologies, Paisley, UK), were transfected with lipo-
somes (Lipofectamine; Life Technologies) containing the expres-
sion construct according to the manufacturer’s instructions. For
analysis of expression levels by FACS
 
Ò
 
, the cells were detached
48–72 h after transfection, washed three times in FACS
 
Ò
 
 buffer
(1% BSA and 0.02% sodium azide in PBS) and resuspended at a
density of 5 
 
3
 
 10
 
6
 
 cells/ml. The cells were then incubated at 4
 
8
 
C
for 30 min with an equal volume (100 
 
m
 
l) of polyclonal anti-
human CD59 antibody at 10 
 
m
 
g/ml in FACS
 
Ò
 
 buffer, and then
washed three times in FACS
 
Ò
 
 buffer prior to incubation at 4
 
8
 
C
for 30 min with FITC-conjugated rabbit anti–mouse IgG at a fi-
nal concentration of 10 
 
m
 
g/ml in FACS
 
Ò
 
 buffer. Fluorescence of
the cells was then analyzed on a FACScan
 
Ò
 
 instrument (Becton
Dickinson, Abingdon, Oxford, UK).
 
Cell Lysis Assay.
 
CHO cells transfected as described above
on day 1 were harvested and replated on day 2, and were then left
until the plates were confluent (generally day 4). Cells were then
washed twice with serum-free medium, incubated in 0.25 ml
complete medium (7.5% FCS) containing a 1/750 dilution of cal-
cein-AM (Molecular Probes; 1 mg/ml stock in DMSO) for 1 h at
37
 
8
 
C, then washed once. Triplicate wells were incubated with ei-
ther medium alone, a 1/5 dilution of normal human serum
(NHS) in medium (no FCS), or with a 1/5 dilution of NHS plus
blocking antibodies (BRIC 229 and MEM43 both at 10 
 
m
 
g/ml).
All wells contained anti-CHO IgG (0.08 
 
m
 
g/ml) in a total vol-
ume of 0.25 ml. Blocking antibodies were not complement-fix-
ing and in the absence of anti-CHO did not trigger NHS lysis.
After a 1-h incubation at 37
 
8
 
C, all fluid was removed from the
cells and transferred to 96-well plates for calcein measurement.
The remaining cells were lysed with 0.25 ml PBS containing
0.1% Triton X-100 during a 15-min incubation at room temper-
ature (RT), then the lysate removed to 96-well plates for calcein
release assay.
 
Calcein Release Assay.
 
Calcein fluorescence of supernatants
was read in a Denley Wellfluor fluorimeter with the excitation
filter set at 485 nm and emission filter at 530 nm. Percent lysis for
each well was calculated as specific calcein release/total calcein
loading, or:
Mean and standard deviations were determined from triplicate
samples.
% lysis
(NHS calcein release    –
background calcein release)
(NHS calcein release    +
detergent calcein release)
------------------------------------------------------ 100 ´ = 
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Competition Assay for Anti-CD59 Antibodies.
 
Individual 24-
well plates were coated with each of the 8 available antibodies at
10 
 
m
 
g/ml in 0.25-ml aliquots in 25 mM sodium carbonate buffer,
pH 9, for 1 h at 37
 
8
 
C. Wells were blocked by incubation in 1%
BSA in PBS/0.1% Tween for 1 h at 37
 
8
 
C and washed twice in
PBS/Tween, once in PBS alone. Human RBC (0.25 ml of a 1%
suspension in PBS), either untreated or preincubated with satu-
rating amounts of each of the antibodies (10 
 
m
 
g/ml, 30 min on
ice, followed by two washes in cold PBS), were added to tripli-
cate wells for each coating antibody (and to uncoated, blocked
wells as control for nonspecific binding) and incubated at 4
 
8
 
C for
1 h. The wells were washed twice in PBS to remove unbound
RBC and then the bound RBC were lysed by addition of water
(0.25 ml, 15 min RT). The lysate was removed to a 96-well
plate, spun to remove ghosts and the absorbance in the superna-
tant measured at 412 nm in a plate reader. For each antibody
combination, results are expressed as a percentage inhibition de-
rived from the ratio of binding of uncoated RBC/antibody-
coated RBC to a particular antibody on the well and are calcu-
lated as:
where: Abs1 
 
5
 
 absorbance in supernatant from antibody-coated
RBC bound to antibody-coated well; Abs2 
 
5
 
 absorbance in su-
pernatant from antibody-coated RBC bound to uncoated well;
Abs3 
 
5
 
 absorbance in supernatant from uncoated RBC bound to
antibody-coated well; Abs4 
 
5
 
 absorbance in supernatant from
uncoated RBC bound to uncoated well. Inhibition was calcu-
lated separately for each of the three triplicates and means and
standard deviations were determined.
 
Antibody Binding Assay.
 
CHO cells were transfected with
each of the mutant constructs as described above. 2 d after trans-
fection the cells were replated and, after two additional days, de-
tached, and washed twice with serum-free medium then incu-
bated in 0.25 ml complete medium (7.5% FCS) with each of the
antibodies (each at approximately 10 
 
m
 
g/ml). Antibody binding
to the cells was confirmed by FACS
 
Ò
 
 as described above.
 
Western Blot.
 
Mutant and wild-type CD59-expressing CHO
% inhibition 100 [{(Abs1 Abs2)/ Abs3 ( Abs4)} 100] ´ , – – – =
 
cells were lysed at 4
 
8
 
C in 1% Triton X-100, 1 
 
m
 
g/ml leupeptin,
1 
 
m
 
g/ml pepstatin A and 1 mM phenlymethylsulphonyl fluoride
in PBS. Aliquots of the precleared lysate were electrophoresed in
non-reducing buffer in 15% SDS-PAGE gels. The proteins were
then electrophoretically transferred to nitrocellulose which was
then probed with anti-human CD59 antibody MEM43. Bound
antibody was detected using a chemiluminescent detection system
(Western-Light, Tropix Inc., Bedford, MA).
 
Statistical Analysis.
 
Student’s 
 
t
 
 test was used to analyze the
data.
 
Results
 
Mutant Design.
 
Since the region(s) of CD59 responsible
for its complement-inhibitory activity are controversial, a
systematic mutational analysis of amino acids distributed
across the entire surface of the extracellular domain of the
protein was undertaken. In using this approach it was as-
sumed that CD59 inhibits MAC formation by binding to
another protein, such as C8 or C9. Since the sites of most
protein–protein interactions that have been characterized
in detail are relatively large (700–900 Å
 
2
 
) (33) and the sur-
face area of CD59 is small (
 
z
 
3200 Å
 
2
 
) (19, 20), it seemed
likely that the entire surface could be scanned with a small
number of mutations. According to this strategy, a first set
of mutations was designed to scan both faces and the edges
of the disk-like domain at low resolution. Based on the re-
sults of the first round of mutagenesis, a second set of muta-
tions was used to analyze specific regions in greater detail.
The selection of particular residues for mutation was
based on several criteria. First, only amino acids with side
chains pointing away from the structural core of the pro-
tein in the NMR structures were chosen. Assuming that
the overall conformation of CD59 in the NMR structure
represents that of CD59 when bound to a putative ligand
Figure 1. Alignment of CD59
species homologs and HVS-15.
Amino acid sequences for the
extracellular regions of human
(22), African green monkey (11),
baboon (11), owl monkey (Gen-
Bank accession number: L22861),
marmoset (GenBank accession
number L22860), squirrel monkey
(6), and rat (23) CD59 and Her-
pesvirus saimiri protein HVS-15
(5) were aligned with the partial
sequences of pig (23) and sheep
(44) CD59. Residues identical in
all sequences are inverse-shaded
black and those that are conserved
in all species with one exception
are inverse-shaded gray. Puta-
tive glycosylation sites are boxed.
Lower case letters represent prob-
able amino acid assignment, and
X represents positions with un-
known sequence (23). Residues
are numbered according to the sequence of the human mature polypeptide. Every tenth residue is indicated, and both the residue number and intro-
duced substitution are listed for each position selected for mutation. Asterisks mark mutations that disrupted the complement-inhibitory function of hu-
man CD59. The sequences were aligned using GCG software (45). 
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(even though the conformations of the side chains are
likely to differ), only side chains of surface residues will di-
rectly participate in binding interactions. Second, given the
observed lack of strict homologous restriction between cer-
tain species (9), it is likely that the active site will include
some residues conserved between species so residues repre-
senting the most highly conserved of the surface amino ac-
ids were selected for mutation (Fig. 1). Third, where pos-
sible, mutations were made in regions of the protein
implicated in CD59 function by others in order to test their
various proposals (19, 20, 23, 31, 32).
Having chosen the sites for mutation, highly nonconser-
vative substitutions were introduced in order to maximize
the chances of identifying residues forming the ligand bind-
ing surface rather than the smaller subset of residues, identi-
fiable by alanine-scanning mutagenesis, that also contribute
significant binding energy to the interaction (35). The like-
lihood that the mutations would disrupt folding was mini-
mized by confining the substitutions to surface residues. As
reasoned previously (36), if a mutant protein is expressed it
can generally be expected to have a native-like structure
since the drastic changes introduced according to this strat-
egy are unlikely to have subtle effects on the protein fold.
The substitutions made in the two rounds of mutagenesis
are shown in Fig. 1.
 
Protective Activity of CD59 Mutants.
 
To facilitate mutant
screening, an assay for CD59 function in cells transiently
expressing wild-type and mutant CD59 genes was devel-
oped. In this assay, transfected cells are loaded with calcein-
AM, a fluorescein-based dye that is converted to the fluo-
rescent compound calcein by esterases in live cells. Calcein
is effectively retained by intact cells but is released into the
medium by lysed cells, where its fluorescence can be mea-
sured. The loaded sensitized cells are incubated with normal
human serum as a source of complement and the extent of
lysis determined by measuring the fluorescence of the re-
leased calcein (see Materials and Methods).
The calcein-release assay was used to measure the ability
of each of the scanning mutants to inhibit complement-
mediated lysis of transiently transfected CHO cells (Fig.
2 
 
A
 
). FACS
 
Ò
 
 analysis indicated that the mutant proteins
were all expressed at the cell surface at similar levels (Table 1).
When the mutant-transfected cells were tested in the cal-
cein-release assay, most were clearly protected from lysis
by the presence of the mutant gene when compared with
cells transfected with the expression vector alone (Fig. 2 
 
A
 
,
 
black bars
 
). Consistent with this, co-incubation with CD59-
blocking antibodies produced statistically significant rever-
sals of the protective effects of these mutants (Fig. 2 
 
A
 
,
 
white bars
 
). These results suggest that most of the scanning
mutations did not disrupt the folding or the protective ac-
tivity of CD59. Although mutant F47E provided statisti-
cally insignificant protection compared to cells not express-
ing CD59 (
 
P
 
 
 
5
 
 0.059), this mutant appeared to have some
activity since a significant increase in lysis occurred in the
presence of blocking antibodies (
 
P
 
 
 
5
 
 0.004). Only one of
the scanning mutants, W40E, completely failed to provide
any protection from complement-mediated lysis. Loss of
the inhibitory property of this mutant is not likely to be
due to misfolding of the protein since it is recognized by
the conformation-sensitive monoclonal antibodies HC1
and MEM43/5 (Table 1). These results indicate that W40
forms at least part of the active site essential for inhibiting
the formation of the MAC by CD59. The weak protective
effect of the mutant F47E suggests that this residue may be
at the periphery of the active site or that it has subtle effects
on the conformation of CD59 which indirectly affect its
activity.
The sidechain of W40 partially fills a cleft formed by the
packing of the 
 
a
 
-helix against the three-stranded 
 
b
 
-sheet
on the glycosylated face of CD59 (19, 20). In a second
round of mutagenesis, residues in and around this cleft,
specifically K38, K41, R53, L54, and E56, were mutated.
Residue D24, which is adjacent to W40 but projects in the
opposite direction, was also mutated because it forms part
of a conserved loop consisting of residues 20-24 (20, 23).
Of these mutants, D24R, R53E, and E56R failed to pro-
vide any protection from complement that was reversible
by co-incubation with CD59-blocking antibodies (Fig. 2 
 
B
 
).
All of the mutations that were tested are represented on the
NMR structure (19) in Fig. 3, 
 
A–C
 
.
 
Antibody Epitopes and Competition Experiments.
 
The bind-
ing sites of antibodies that block the complement-inhibi-
Figure 2. Protection of CD59 mutant-transfected cells from lysis by
complement. (A) First-round scanning mutations; (B) second-round mu-
tations. CHO cells transfected with mutant CD59 genes were loaded
with calcein-AM and then subjected to complement attack as described in
the Materials and Methods. Percent lysis was calculated from the fluores-
cence of calcein released by cell lysis as a fraction of total calcein loading
as also described in Materials and Methods. For all mutants, the total fluo-
rescence per well was similar to the wild-type value. Mean and standard
deviations of % lysis in the presence of NHS alone (filled bars) or in the
presence of NHS 1 anti-CD59 blocking antibodies (open bars) were cal-
culated from triplicate samples in a single experiment. Asterisks identify
mutants which do not protect cells from lysis. Results are from a single
experiment; independent replications gave similar results. 
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tory activity of CD59 are likely to at least partially overlap
with the active site of CD59, while epitopes of non-block-
ing antibodies are expected to lie in a region distinct from
the active site. A map of the epitopes of such antibodies can
therefore be used to independently confirm the location of
the putative active site. A panel of anti-CD59 monoclonal
antibodies with differing capacity to block the protective ef-
fects of CD59 was selected for this purpose. The panel
consists of the antibodies YTH53.1, BRIC 229, MEM43,
HC2, and 2/24, which all have strong CD59-blocking ac-
tivity, A35, which blocks weakly, and HC1 and MEM43/5,
which have no CD59-blocking activity (Morgan, B.P., un-
published data).
The antibodies were first characterized in a competition
assay (Table 2). Competition between the antibodies was
determined by measuring the ability of each antibody,
prebound to human RBC, to inhibit the binding of the
RBC to plates treated with a second anti-CD59 antibody.
Whereas none of the blocking anti-CD59 antibodies com-
peted strongly for binding with the non-blocking antibod-
ies, most pairs of the blocking antibodies were competitive,
as observed previously with a subset of these antibodies
(37), and consistent with the existence of a single active site
on CD59. The only pair of blocking antibodies for which
competition was not observed was HC2 and BRIC 229.
The possibility that HC2 has relatively weak affinity is sug-
gested by the observation that strong competition for bind-
ing sites on HC2-coated RBC only occurred on plates
coated with the weakly-blocking antibody, A35.
The antibody epitopes were mapped by measuring the
ability of each antibody to bind to CHO cells transfected
with each of the mutants. Although this approach cannot
delineate their borders precisely, the data show that the
epitopes of the blocking antibodies are overlapping but dis-
tinct (Table 1 and Fig. 4). All include W40, plus differing
portions of continuous surface defined by R53 and other
residues adjacent to or in close proximity to W40, suggest-
ing that this region overlaps with the active site of CD59.
This is consistent with the results of the calcein-release as-
say, in which mutants W40E and R53E were unable to
protect cells from complement-mediated lysis. It may be
significant, however, that mutation of D24 to R did not
prevent the binding of any of the blocking antibodies, al-
though this change disrupts CD59 activity. The binding
data also indicate that the epitopes of the non-blocking an-
tibodies both lie in a distinct region of the protein which
includes L33. However, mutation of E56 to R, which dis-
rupts the function of CD59, also prevents binding of the
non-blocking antibody HC1. This implies that the epitope
of HC1 and the active site of CD59 partially overlap but in
such a way that antibody binding does not completely
block CD59 activity. Although the epitope for HC1 ap-
pears discontinuous in the figure, this cannot be concluded
since the role of intervening residues in antibody binding
was not tested.
 
The Role of Glycosylation.
 
To test the role of the glycans
at the highly conserved 
 
N
 
-glycosylation site in the comple-
ment-inhibitory function of CD59, N18 was mutated to
 
Table 1.
 
Mapping of Anti-CD59 Antibody Epitopes
 
Antibody
Mutant
Y4R N8R D12R N18Q F23R D24R L33E K38E W40E K41D F42K F47E R53E L54D E56R N57K Y62R Wt Vector
 
% positive
 
Polyclonal 40 35 46 49 42 49 52 30 38 46 44 50 47 50 47 48 44 51 0
BRIC 229 70 71 70 65 66 72 82 52 0 75 69 74 60 62 79 77 75 78 7
YTH 53.1 70 60 68 62 53 64 70 47 16 55 65 74 32 52 74 74 66 77 0
MEM43 82 84 81 80 45 83 89 67 6 45 82 84 17 63 87 87 86 86 0
A35 42 48 49 46 51 60 64 27 5 38 54 54 8 17 35 62 53 58 11
HC2 62 65 61 60 6 74 78 42 0 66 65 68 4 19 54 70 62 68 11
2/24 65 66 65 64 12 70 77 54 0 0 68 72 11 27 67 68 67 68 4
HC1 67 70 62 67 60 73 23 53 44 74 68 72 79 27 6 70 63 72 0
MEM43/5 80 83 76 82 74 84 9 68 61 85 82 84 88 86 83 86 84 87 6
2nd Ab 1 1 1 1 0 1 0 0 1 0 1 1 0 1 0 1 0 1 0
Binding of antibodies to mutant-transfected cells was assessed by FACS
 
Ò
 
 analysis and % positive cells listed. Mutants showing 
 
,
 
33% reactivity with a
given antibody compared to wild-type cells labeled with the same antibody are shaded black, and mutants with intermediate reactivity (34–52% of
wild-type) are shaded gray. Results are from a single experiment; independent replications gave similar results. 
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Q. The N18Q mutant form of CD59 runs as a single sharp
band of z14 kD on SDS-PAGE, at least 5 kD smaller than
wild-type CD59 expressed in CHO cells, which runs as a
ladder of bands in the molecular mass range 20–25 kD, and
erythrocyte CD59, which runs as a broad smear in the mo-
lecular mass range 19–25 kD (Fig. 5). The mobility and
banding patterns of all of the other mutants were indistin-
guishable from those of wild-type CD59 (data not shown).
The mobility of N18Q CD59 is similar to that of deglyco-
sylated CD59 (28), indicating that the mutant is not glyco-
sylated. The expression of mutant N18Q at the cell surface,
where it binds all of the polyclonal and monoclonal anti-
bodies (Table 1), demonstrates that N-glycosylation is not
required for native-like folding and expression of human
CD59. Mutant N18Q retains wild-type levels of comple-
ment-inhibitory activity (Fig. 2 B) and binds all of the block-
ing antibodies at levels similar to that of wild-type CD59
(Table 1), suggesting that the N-glycan does not contribute
to the active site. This is consistent with the ability of
YTH53.1 and BRIC 229 to immunoblot CD59 from en-
doglycosidase F-treated erythrocytes (37). These data sug-
gest that N-glycosylation is not required for the mainte-
nance of the structure or complement-inhibitory function
of human CD59.
Discussion
CD59 blocks the complement-mediated lysis of host cells
by preventing assembly of the MAC, presumably through
binding to C8 and/or C9 molecules in the nascent com-
plex and preventing recruitment of the additional C9 mol-
ecules required for pore formation. Whilst it remains for-
Figure 3. Location and properties of the proposed active site of CD59. (A–C) Mutagenesis data. The residues which were mutated are all numbered
and those whose mutation reduced protection (* in Fig. 1) or had no effect are colored red and light blue, respectively. N18, which is N-glycosylated, is
colored green. Back (B) and side (C) views differ from the front view (A) by 1808 and 908, respectively. (D) Chemical features. Hydrophobic residues are
colored green, polar uncharged residues, light blue, positively charged residues, dark blue, and negatively charged residues, red. The view is the same as
in A. (E) Conserved residues. Non-cysteine residues that are conserved in all known CD59 sequences and HVS-15 (inverse-shaded black in Fig. 1) are
colored red and those conserved in all sequences with one exception (inverse-shaded gray in Fig. 1) are colored orange. Cysteine residues, which are also
conserved in all sequences, are colored yellow. The view is the same as in A. (F) Secondary structure. The positions of the two- and three-stranded b-sheets
(purple and red, respectively) and the a-helix (dark blue) of CD59 are shown. Loop residues are colored light blue. The view is the same as in A. All of the
experimental data are superimposed on the lowest energy NMR structure (19) drawn using Rasmol (46).513 Bodian et al.
mally possible that CD59 has two distinct binding sites for
C8 and C9, the present data strongly suggest that there is a
single active site and that this site lies in the vicinity of W40.
Mutation of W40 to E eliminates the complement-inhibi-
tory function of CD59 and prevents the binding of all the
function blocking anti-CD59 antibodies tested. Although
W40 is partially buried in the low resolution NMR struc-
tures (19, 20), its mutation to E results in a protein that is
probably folded in a predominantly native-like structure
Table 2. Antibody Competition and Blocking Ability
Plate
Antibody Blocks
RBC Antibody
BRIC229 YTH53.1 MEM43 HC2 2/24 A35 HC1 MEM43/5
% inhibition
BRIC 229 Yes 88 6 3 71 6 5 58 6 7 21 6 3 17 6 31 1 6  2 12 6 50  6  4
YTH 53.1 Yes 79 6 5 79 6 7 65 6 3 40 6 6 39 6 64  6  32  6  52  6  3
MEM43 Yes 68 6 6 49 6 7 79 6 3 5 6 3 62 6 6 44 6 30  6  2 12 6 2
HC2 Yes 15 6 3 36 6 5  66 6 3 78 6 5 0 6 1 71 6 9 11 6 4 17 6 4
2/24 Yes 68 6 5 79 6 9 85 6 6 45 6 2 75 6 5 88 6 3 12 6 4 16 6 6
A35 Weakly 81 6 3 72 6 2 77 6 5 88 6 4 15 6 3 87 6 5 17 6 38  6  2
HC1 No 21 6 40  6  28  6  2 25 6 30  6  9 40 6 4 73 6 6 11 6 3
MEM43/5 No 13 6 30  6  67  6  3 12 6 5 15 6 3 29 6 5 17 6 4 79 6 5
Antibody-coated RBC were bound to antibody-coated plates and inhibition of binding calculated as described in Materials and Methods. Black
shading highlights strong competition (.50% inhibition of binding). Lower levels of inhibition (30–50%), shaded gray, may result from weak com-
petition. Blocking activity is summarized from previously published and unpublished data.
Figure 5. Western-blot analysis of mutant N18Q. CHO cells trans-
fected with the expression vector alone or with the vector expressing wild-
type or mutant N18Q CD59 were solubilized and subjected to SDS-PAGE
along with purified erythrocyte CD59 and then Western-blotted with anti-
CD59 antibody MEM43 as described in the Materials and Methods.
Lanes  1,  2, and 3 contained 500, 100, and 50 ng of erythrocyte CD59, re-
spectively. Lanes 4, 5, and 6 contained aliquots of the cell lysate corre-
sponding to z5 3 105 CHO cells transfected with the expression vector
alone or with the vector expressing mutant N18Q or wild-type CD59,
respectively.
Figure 4. The epitopes of anti-CD59 function-blocking mAb cluster
in the region of the proposed active site of CD59. Residues whose muta-
tion disrupted the binding of each antibody (inverse shaded black in Table 1)
are shaded black and those whose mutation led to reduced levels of bind-
ing (shaded gray in Table 1) are shaded gray. Only antibodies HC1 and
MEM43/5 have no CD59-blocking ability. In the last panel, all of the
residues that were mutated are shaded gray except for the visible residues
whose mutation disrupted the function of CD59 which are shaded black
and labeled. In each panel the protein face shown is the one containing
the proposed active site shown in the same view as in Fig. 3 A. The ex-
perimental data are superimposed on the lowest energy NMR structure
(19) drawn using Rasmol (46).514 Mutational Analysis of CD59
since it is expressed at the cell surface and is recognized by
the polyclonal antiserum and both of the non-blocking
antibodies to similar extents (60–75% of the wild-type
level, Table 1). Mutation of the adjacent residue, R53,
which clearly protrudes away from the core of the structure
(19, 20), to E also inhibits the complement-inhibitory ac-
tivity and reduces the binding of four of the six CD59-
blocking antibodies, implicating this residue as part of the
active site of CD59. A third residue likely to be involved is
E56, which lies only 7.5 Å (Ca-Ca) from R53 on the
same face of the protein. However, E56 must lie at the pe-
riphery of the active site because it constitutes part of the
epitope of a non-blocking antibody (Table 1; Fig. 4).
Moreover, on the basis of recent carbohydrate analyses of
erythrocyte CD59, it has been proposed that, in some tis-
sues, residues T51 and T52, which occupy the region be-
tween E56 and R53 but were not mutated in the present
study, may be O-glycosylated (37a). If this is the case the
O-linked glycans are likely to disrupt any contiguous pro-
tein surface that includes W40, R53 and E56.
The role of the fourth residue whose mutation disrupted
the function of CD59, D24, is less clear as this residue does
not form part of a contiguous surface with W40, R53 and
E56 (Fig. 3). D24 lies on the edge of the extracellular do-
main of CD59 only 6 Å from W40 (Ca-Ca; Fig. 3, A–C)
but is separated from this residue by F23, K41, and F42, all
of which were mutated without disrupting the function of
the protein. Several explanations could account for this ob-
servation. First, it is possible that D24 is part of a discontin-
uous active site, or that CD59 has a second active site
which includes D24. However, both possibilities seem un-
likely since none of the epitopes of the panel of six block-
ing antibodies includes D24. Second, it is conceivable that
the mutation of D24 indirectly alters the conformation of
key active site residues. However, conformational effects, if
these were to occur at all, can only be very restricted given
that the D24R mutant binds a series of conformation-sensi-
tive antibodies (Table 1). Finally, the possibility needs to be
considered that residue D24, which forms part of a flexible
loop (19, 20), is in a sufficiently mobile region of the mole-
cule to allow its direct involvement in forming the active
site. Additional experiments are required to determine the
role of D24 in the inhibition of complement-mediated lysis.
The affinity of CD59 for the nascent MAC has not been
measured directly, although it has been shown that soluble
forms of CD59 block the formation of the MAC at rela-
tively low concentrations (z0.5 mM [27]). This suggests
that CD59 participates in a protein–protein interaction of
relatively high affinity compared to other cell surface pro-
tein–protein interactions (38). Sites of protein–protein in-
teraction are often defined by regions of hydrophobic and
irregular protein surface (33). In the NMR structures of
human CD59 W40 lies at the base of a hydrophobic
groove, formed by residues F23, C39, W40, and L54,
which is lined on one side by a ridge of hydrophilic resi-
dues (K41, H44, R53 and R55; Fig. 3 D). Sequence align-
ments suggest that the hydrophobic groove is among the
best conserved regions of CD59 (Fig. 3 E) with only F23
exhibiting any variation among the fully sequenced homo-
logues (substitutions to leucine or glutamine; reference 23,
Fig. 1). Given the relatively poor overall levels of CD59 se-
quence conservation and the observed lack of strict homol-
ogous restriction between species with known sequences,
the conserved hydrophobic groove centred on W40 repre-
sents a reasonable candidate for the active site of CD59.
Residues 53 and 56, which vary to some extent between
species, may contribute some specificity to recognition by
CD59. Although mutation of residues F23 and L54, which
form part of this hydrophobic groove, did not abrogate the
activity of CD59, the putative active site may not have se-
vere topological constraints and, given that these residues
are located at the ends of the groove, it is conceivable that
the mutants retained sufficient hydrophobic character to be
functional.
The NMR analysis of a form of CD59 which includes at
least part of the non-lipid component of the GPI-anchor
indicated that much of the seven residue COOH-terminal
stalk is packed against the non-glycosylated face of the ex-
tracellular domain of the molecule (20). This organization
of the molecule places the glycosylated face containing the
proposed active site in a well exposed, membrane distal po-
sition. The NMR study also indicated that in all calculated
structures containing model oligosaccharides similar to those
present on the protein, the region of the proposed active
site remains fully exposed. Consistent with this, the normal
expression and full activity of the unglycosylated mutant,
N18Q, suggests that the N-linked glycan does not directly
contribute to protein folding or complement inhibition by
CD59. However, the bulk of the N-linked glycan would
be expected to dampen any flexibility at the base of the
stalk which could, in turn, keep the extracellular domain in
an optimal orientation for interaction with the nascent
MAC. Removal of the N-linked glycan could therefore be
expected to reduce the affinity of this interaction without
eliminating it completely. A partial reduction in the affinity
of the N18Q mutant for the MAC could be masked by
overexpression of the protein and therefore might have
gone undetected in the present study. An indirect role for
the N-linked glycan in facilitating the inhibition of com-
plement by CD59 may account for the conservation of the
glycosylation site but fails to explain the observation that
the enzymatically deglycosylated protein loses most of its
activity (25).
The structural analyses of CD59 confirmed that Ly-6SF
proteins have topological similarities to snake venom neu-
rotoxins (19, 20). In the crystal structure of a complex be-
tween the snake toxin fasciculin and its receptor acetylcho-
linesterase, the residues that contact the receptor lie on the
concave face of the toxin (39). The analogous face is the
site of the proposed active site of CD59. Examples of con-
served active site locations have been noted previously for
other protein–protein recognition molecules including, for
example, immunoglobulin superfamily adhesion molecules
and cadherins (40, 41). However, the fasciculin-acetylcho-515 Bodian et al.
linesterase crystal structure (39) and functional studies of
modified forms of other neurotoxins (42, 43) have revealed
that the primary contacts between the toxins and their re-
ceptors involve residues of loop II, defined as strands C and D
and their connecting loop. In contrast, in CD59, the
equivalent loop is significantly shorter and the proposed ac-
tive site lies instead on the loop between strands D and E
on the opposite end of the face. This loop is significantly
longer and more elaborate than the corresponding loop in
the neurotoxins, which lack the a-helix in this region.
These results suggest, not unexpectedly, that the determi-
nants of ligand recognition have diversified considerably
since the emergence of protein–protein recognition mole-
cules with this topology.
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